CeleCor Therapeutics, Inc.
CeleCor Therapeutics develops zalunfiban, an investigational next-generation GPIIb/IIIa platelet inhibitor designed for pre-hospital treatment of STEMI heart attacks.
Funding history
About CeleCor Therapeutics, Inc.
How much funding has CeleCor Therapeutics, Inc. raised?
CeleCor Therapeutics, Inc. has raised $63.3M in total funding. The most recent round was Series A.
Where is CeleCor Therapeutics, Inc. headquartered?
CeleCor Therapeutics, Inc. is headquartered in Del Mar, CA.
What does CeleCor Therapeutics, Inc. do?
CeleCor Therapeutics develops zalunfiban, an investigational next-generation GPIIb/IIIa platelet inhibitor designed for pre-hospital treatment of STEMI heart attacks.
What problem does CeleCor Therapeutics, Inc. solve?
There is a time-to-treatment gap for the 800,000 people in the U.S. who have a heart attack (STEMI) each year, since effective treatment isn't available at the first point of medical contact before reaching a hospital.
What's CeleCor Therapeutics, Inc.'s solution?
CeleCor is developing zalunfiban, an investigational subcutaneously-injected platelet inhibitor for pre-hospital treatment of STEMI heart attacks, across multiple pre-PCI settings.
What makes CeleCor Therapeutics, Inc. different?
Zalunfiban is a next-generation GPIIb/IIIa platelet inhibitor engineered to reach maximal effect within 15 minutes of injection while its antiplatelet effect wears off in about two hours.
What makes CeleCor Therapeutics, Inc. notable?
Co-founded by biomedical engineer Robert S. Hillman, PhD; developing devices/therapies to get STEMI heart-attack patients to treatment with open coronary arteries, and has raised $58.4M.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
